ISSUE 1339
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol (Symbicort). A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
STANDARD TREATMENT — Patients with mild, intermittent symptoms of COPD are generally treated with inhaled bronchodilators, usually a short-acting beta2-agonist such as albuterol (Proventil, and others), a short-acting anticholinergic such as ipratropium (Atrovent HFA, and others), or sometimes both (Combivent). When symptoms become more severe or persistent, many experts prescribe a long-acting beta2-agonist such as salmeterol
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1339b
Electronic, downloadable article - $45